The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative respiratory health organizations. Key sources included the US Food & Drug Administration (FDA) Centre for Drug Evaluation and Research (CDER), European Medicines Agency (EMA) Human Medicines Division, World Health Organization (WHO) Global Health Observatory, Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI), National Center for Biotechnology Information (NCBI/PubMed), European Centre for Disease Prevention and Control (ECDC), American Lung Association (ALA) Epidemiology and Statistics Unit, European Respiratory Society (ERS) White Papers, American Thoracic Society (ATS) Clinical Guidelines, Global Initiative for Asthma (GINA) Reports, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy Documents, International Society for Aerosols in Medicine (ISAM) Publications, IQVIA National Prescription Audit, IMS Health MIDAS Database, and national health ministry reports from key markets (NHS UK, CMS US, NHI Japan).
These sources were employed to gather prescription statistics, regulatory approval data for MDI and DPI devices, clinical efficacy studies for bronchodilators and corticosteroids, asthma/COPD prevalence trends, reimbursement policies, and competitive landscape analysis for manually operated versus digitally operated inhaler technologies.
Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Product Development, regulatory affairs chiefs, and commercial directors from respiratory inhaler manufacturers (including MDI and DPI device developers) and pharmaceutical OEMs. Medical directors from respiratory care centers, procurement leads from hospitals and clinics, board-certified pulmonologists, respiratory therapists, asthma and COPD specialists, and hospital pharmacy directors comprised demand-side sources. Market segmentation was validated across inhaler types, connected/digital inhaler pipeline timelines were confirmed, and insights on clinical prescription patterns, patient adherence monitoring, pricing strategies, and reimbursement dynamics for asthma versus COPD indications were gathered through primary research.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
By Region: North America (38%), Europe (25%), Asia-Pacific (28%), Rest of World (9%)
Revenue mapping and prescription volume analysis were implemented to determine global market valuation. The methodology comprised the following:
Identification of over 40 significant manufacturers in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa
Product mapping for the following categories: nebulizers, dry powder inhalers (DPI), soft mist inhalers, and metered dose inhalers (MDI)
Evaluation of annual revenues that are specific to respiratory inhaler portfolios, including connected/digital inhaler segments, as reported and modeled
Manufacturers that account for 65-70% of the global market share in 2024 are included in the coverage.
Derive segment-specific valuations for asthma management versus COPD treatment applications through extrapolation using bottom-up (prescription volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches.
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile").
In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
ケーススタディ
Aerospace & Defense